Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05722015
Other study ID # 3475A-D77
Secondary ID 2022-501506-36-0
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date February 14, 2023
Est. completion date May 22, 2028

Study information

Verified date February 2024
Source Merck Sharp & Dohme LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to assess the pharmacokinetics (PK) and safety of SC MK-3475A vs intravenous (IV) pembrolizumab, administered with chemotherapy in first line treatment of adult participants with metastatic non-small cell lung cancer. The primary hypotheses of this study are MK-3475A subcutaneous (SC) is noninferior to pembrolizumab IV with respect to PK parameters.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 378
Est. completion date May 22, 2028
Est. primary completion date September 23, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility The key inclusion and exclusion criteria include but are not limited to the following: Inclusion Criteria: - Has histologically or cytologically confirmed diagnosis of squamous or non-squamous Non-small Cell Lung Cancer (NSCLC). - Must provide archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated. - Has a life expectancy of at least 3 months. Exclusion Criteria: - Has a diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements. - Has received prior systemic anticancer therapy for metastatic NSCLC. - Has received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization. - Has received prior radiotherapy within 2 weeks of start of study intervention or has radiation-related toxicity requiring corticosteroids. - Has received radiation therapy to the lung (>30 Gray) within 6 months of start of study intervention. - Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. - Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy. - Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. - Has an active autoimmune disease that has required systemic treatment in past 2 years. - Has an active infection requiring systemic therapy. - Has a history of human immunodeficiency virus (HIV) infection. - Has a history of Hepatitis B or C. - Has not adequately recovered from major surgery or has ongoing surgical complications. - Has a history of allogenic tissue/solid organ transplant.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Pembrolizumab coformulated with hyaluronidase
MK3475A SC will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
Drug:
Pemetrexed
Pemetrexed 500 mg/m² by IV Infusion will be administered for nonsquamous NSCLC as per the schedule specified in arm.
Cisplatin
Cisplatin 75 mg/m² by IV Infusion will be administered for nonsquamous and squamous NSCLC as per the schedule specified in arm.
Carboplatin
Carboplatin AUC 5 mg/mL/min in nonsquamous and AUC 6 mg/mL/min in squamous NSCLC will be administered as per the schedule specified in arm.
Paclitaxel
Paclitaxel 200 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
Nab-paclitaxel
Nab-paclitaxel 100 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
Biological:
Pembrolizumab
Pembrolizumab by IV Infusion will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
Drug:
Filgrastim
Filgrastim will be administered as per the schedule specified for the arm.
Pegylated filgrastim
Pegylated filgrastim will be administered as per the schedule specified for the arm.

Locations

Country Name City State
Argentina Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 1005) ABB Caba
Argentina Instituto Argentino de Diagnóstico y Tratamiento (IADT) ( Site 1002) Buenos Aires
Argentina Clinica Adventista Belgrano-Oncology ( Site 1004) Caba
Argentina Instituto Alexander Fleming ( Site 1008) Ciudad Autónoma de Buenos Aires Buenos Aires
Argentina Hospital Italiano de Córdoba ( Site 1000) Cordoba
Argentina Instituto de Investigaciones Clínicas Mar del Plata ( Site 1001) Mar del Plata Buenos Aires
Argentina Sanatorio Parque ( Site 1003) Rosario Santa Fe
Brazil CRIO - CENTRO REGIONAL INTEGRADO DE ONCOLOGIA-Pesquisa Clínica ( Site 1102) Fortaleza Ceara
Brazil Instituto Joinvilense de Hematologia e Oncologia ( Site 1101) Joinville Santa Catarina
Brazil Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 1100) Porto Alegre Rio Grande Do Sul
Brazil Hospital de Câncer de Recife ( Site 1107) Recife Pernambuco
Brazil A. C. Camargo Cancer Center ( Site 1106) Sao Paulo
Chile IC La Serena Research ( Site 1207) La Serena Coquimbo
Chile Bradfordhill-Clinical Area ( Site 1202) Santiago Region M. De Santiago
Chile FALP-UIDO ( Site 1203) Santiago Region M. De Santiago
Chile Instituto Nacional del Cancer-CR Investigación ( Site 1211) Santiago Region M. De Santiago
Chile Oncovida ( Site 1209) Santiago Region M. De Santiago
Chile Pontificia Universidad Catolica de Chile-Hemato-Oncology ( Site 1210) Santiago Region M. De Santiago
Chile Oncocentro Valdivia ( Site 1201) Valdivia Los Rios
China Beijing Cancer hospital-intrathoratic deparmtment II ( Site 4510) Beijing Beijing
China Beijing Chest Hospital,Capital Medical University ( Site 4511) Beijing Beijing
China Beijing Peking Union Medical College Hospital-pneumology department ( Site 4501) Beijing Beijing
China Fujian Provincial Cancer Hospital ( Site 4517) Fuzhou Fujian
China Southern Medical University Nanfang Hospital-Depatrment of Respiratory and Critical Care Medicine ( Guangzhou Guangdong
China The First Affiliated Hospital, Zhejiang University-Respiratory Department ( Site 4514) Hangzhou Zhejiang
China Anhui Provincial Hospital-Cancer Chemotherapy Department ( Site 4503) Hefei Anhui
China Jiangmen Center Hospital ( Site 4509) Jiangmen Guangdong
China The First Affiliated Hospital of Nanchang University-Respiratory Medicine Department ( Site 4515) Nanchang Jiangxi
China Fudan University Shanghai Cancer Center-Oncology ( Site 4512) Shanghai Shanghai
China ShenZhen People's Hospital ( Site 4504) Shenzhen Guangdong
China Shanxi Cancer Hospital ( Site 4521) Taiyuan Shanxi
China Taizhou Hospital of Zhejiang Province-Respiratory ( Site 4508) Taizhou Zhejiang
China Tianjin Chest Hospital ( Site 4518) Tianjin Tianjin
China Chongqing Three Gorges Central Hospital ( Site 4516) Wanzhou Chongqing
China Wuhan Union Hospital Cancer Center-Cancer center ( Site 4502) Wuhan Hubei
China The First Affiliated Hospital of Xi'an Jiaotong University ( Site 4520) Xi'an Shaanxi
France Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 2603) Paris
France Centre Hospitalier de Cornouaille Quimper - Concarneau ( Site 2600) Quimper Finistere
France Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau ( Site 2602) Tours Indre-et-Loire
Guatemala Private Practice- Dr. Rixci Augusto Lenin Ramírez ( Site 1404) Ciudad de Guatemala
Guatemala MEDI-K CAYALA ( Site 1403) Guatemala
Guatemala Centro Medico Integral De Cancerología (CEMIC) ( Site 1400) Quetzaltenango
Guatemala Centro Regional de Sub Especialidades Médicas SA ( Site 1401) Quetzaltenango
Hungary Országos Korányi Pulmonológiai Intézet-VI. Tüdöbelosztály és Bronchológia ( Site 2100) Budapest
Hungary Semmelweis Egyetem-Pulmonológiai Klinika ( Site 2104) Budapest
Hungary Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 2102) Kecskemét Bacs-Kiskun
Hungary Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Onkologiai Kozpont ( Site 2103) Szolnok Jasz-Nagykun-Szolnok
Hungary Törökbálinti Tüdogyógyintézet ( Site 2105) Törökbálint Pest
Japan Juntendo University Hospital ( Site 4413) Bunkyo-ku Tokyo
Japan National Hospital Organization Kyushu Cancer Center ( Site 4410) Fukuoka
Japan National Hospital Organization Kyushu Medical Center ( Site 4411) Fukuoka
Japan Kansai Medical University Hospital ( Site 4408) Hirakata Osaka
Japan Saitama Prefectural Cancer Center ( Site 4402) Ina-machi Saitama
Japan Kurashiki Central Hospital ( Site 4409) Kurashiki Okayama
Japan Kurume University Hospital ( Site 4412) Kurume Fukuoka
Japan Shizuoka Cancer Center ( Site 4405) Nagaizumi-cho,Sunto-gun Shizuoka
Japan Miyagi Cancer Center ( Site 4401) Natori Miyagi
Japan Osaka International Cancer Institute ( Site 4407) Osaka
Japan Gunma Prefectural Cancer Center ( Site 4416) Otashi Gunma
Japan National Hospital Organization Hokkaido Cancer Center ( Site 4415) Sapporo Hokkaido
Japan Sendai Kousei Hospital ( Site 4400) Sendai Miyagi
Japan Osaka Medical and Pharmaceutical University Hospital ( Site 4414) Takatsuki Osaka
Japan Nippon Medical School Hospital ( Site 4403) Tokyo
Japan Fujita Health University ( Site 4406) Toyoake Aichi
Japan Tochigi Cancer Center ( Site 4417) Utsunomiya Tochigi
Japan Kanagawa Cardiovascular and Respiratory Center ( Site 4404) Yokohama Kanagawa
Poland Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 2801) Koszalin Zachodniopomorskie
Poland Warminsko - Mazurskie Centrum Chorób Pluc w Olsztynie-Oddzial Onkologii z Pododdzialem Chemioterapii Olsztyn Warminsko-mazurskie
Poland Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier Warszawa Mazowieckie
Romania Institutul Oncologic-Oncologie Medicala ( Site 2302) Cluj
Romania Centrul de Oncologie "Sfântul Nectarie"-Medical Oncology ( Site 2301) Craiova Dolj
Romania SC Radiotherapy Center Cluj SRL-Oncologie Medicala ( Site 2303) Flore?ti Cluj
Romania Cabinet Medical Oncomed ( Site 2305) Timi?oara Timis
South Africa Cape Town Oncology Trials ( Site 2902) Cape Town Western Cape
South Africa The Oncology Centre ( Site 2901) Durban Kwazulu-Natal
South Africa Medical Oncology Centre of Rosebank ( Site 2907) Johannesburg Gauteng
South Africa CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE ( Site 2903) Port Elizabeth Eastern Cape
South Africa Steve Biko Academic Hospital-Medical Oncology ( Site 2904) Pretoria Gauteng
South Africa Sandton Oncology Medical Group (Pty) Ltd-Research ( Site 2900) Sandton Gauteng
Spain Hospital Universitari Vall d'Hebron-Oncology ( Site 2400) Barcelona
Spain Hospital Universitario Juan Ramon Jimenez-Oncología Medica ( Site 2402) Huelva
Spain HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON-ONCOLOGY ( Site 2401) Madrid Madrid, Comunidad De
Spain CHUS - Hospital Clinico Universitario-Servicio de Oncologia ( Site 2404) Santiago de Compostela La Coruna
Taiwan Changhua Christian Hospital ( Site 4203) Changhua County Changhua
Taiwan E-Da hospital ( Site 4208) Kaohsiung
Taiwan Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 4207) Kaohsiung
Taiwan Chang Gung Memorial Hospital at Kaohsiung ( Site 4200) Kaohsiung Niao Sung Dist Kaohsiung
Taiwan National Cheng Kung University Hospital ( Site 4202) Tainan
Taiwan National Taiwan University Hospital-Oncology ( Site 4204) Taipei
Taiwan National Taiwan University Cancer Center (NTUCC) ( Site 4205) Taipei City Taipei
Thailand Chulalongkorn University ( Site 4301) Bangkok Krung Thep Maha Nakhon
Thailand Songklanagarind hospital ( Site 4302) Hatyai Songkhla
Thailand Maharaj Nakorn Chiang Mai Hospital ( Site 4300) Muang Chiang Mai
Thailand Division of Medical Oncology, Siriraj H ( Site 4303) Siriraj Krung Thep Maha Nakhon
Turkey Ankara City Hospital-Medical Oncology ( Site 2501) Ankara
Turkey Gulhane Egitim Arastirma Hastanesi-Oncology ( Site 2504) Ankara
Turkey Hacettepe Universite Hastaneleri-oncology hospital ( Site 2506) Ankara
Turkey TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2502) Istanbul
Turkey I.E.U. Medical Point Hastanesi-Oncology ( Site 2507) Izmir, Karsiyaka Izmir
Turkey Memorial Kayseri Hastanesi ( Site 2500) Kayseri
Turkey Inönü Üniversitesi Turgut Özal Tip Merkezi-medical oncology depertmant ( Site 2503) Malatya
United States Central Care Cancer Center - Bolivar ( Site 0017) Bolivar Missouri
United States University of Illinois at Chicago-University of Illinois Cancer Center ( Site 0022) Chicago Illinois
United States Clermont Oncology Center ( Site 0018) Clermont Florida
United States Hattiesburg Clinic Hematology/Oncology ( Site 0008) Hattiesburg Mississippi
United States Franciscan Health Lafayette East ( Site 0020) Lafayette Indiana
United States Mid Florida Hematology and Oncology Center ( Site 0010) Orange City Florida
United States Mercy Health-Paducah Medical Oncology and Hematology ( Site 0006) Paducah Kentucky
United States St. Joseph's Hospital and Medical Center-Dignity Health Cancer Institute ( Site 0023) Phoenix Arizona
United States Orchard Healthcare Research Inc. ( Site 0011) Skokie Illinois

Sponsors (1)

Lead Sponsor Collaborator
Merck Sharp & Dohme LLC

Countries where clinical trial is conducted

United States,  Argentina,  Brazil,  Chile,  China,  France,  Guatemala,  Hungary,  Japan,  Poland,  Romania,  South Africa,  Spain,  Taiwan,  Thailand,  Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area Under the Curve (AUC) of Pembrolizumab Measured After the First Dose AUC is defined as area under curve exposure. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine AUC. At designated time points (Up to ~14 months).
Primary Trough Concentration (Ctrough) of Pembrolizumab Measured at Steady State Ctrough is defined as the trough concentration at steady-state. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Ctrough. At designated time points (Up to ~18 months)
Secondary Maximum Serum Concentration (Cmax) of Pembrolizumab Measured After the First Dose Cmax is defined as the peak concentration over the dosing interval. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Cmax. At designated time points (Up to ~28 months)
Secondary Trough Concentration (Ctrough) of Pembrolizumab Measured After the First Dose Ctrough is defined as the trough concentration. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Ctrough. At designated time points (Up to ~28 months)
Secondary Area Under the Curve (AUC) of Pembrolizumab Measured at Steady State AUC is defined as area under curve exposure at steady state. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine AUC. At designated time points (Up to ~28 months)
Secondary Maximum Serum Concentration (Cmax) of Pembrolizumab Measured at Steady State Cmax is defined as the peak concentration over the dosing interval in steady-state. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Cmax At designated time points (Up to ~28 months)
Secondary Number of Participants Who Test Positive for Anti-Drug Antibodies (ADAs) for Pembrolizumab Blood samples are to be collected at designated time points for the determination of the presence or absence of anti-pembrolizumab antibodies. The percentage of participants who develop anti pembrolizumab antibodies will be reported. At designated time points (Up to ~28 months)
Secondary Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) The ORR is defined as the percentage of participants who achieve a confirmed CR or PR per RECIST 1.1 as assessed by BICR. Up to~60 months
Secondary Progression-free Survival (PFS) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 by BICR or death due to any cause, whichever occurs first. Up to~60 months
Secondary Overall Survival (OS) OS is defined as the time from randomization to death due to any cause. Up to~60 months
Secondary Duration of Response (DOR) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) For participants who show confirmed CR or PR, DOR is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first. Up to~60 months
Secondary Number of Participants Who Experienced at Least One Adverse Event (AE) An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with an AE will be reported for Arms 1 and 2. Up to~28 months
Secondary Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE) An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported for Arms 1 and 2. Up to~25 months
Secondary Change From Baseline in the European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) Score-Items 29 and 30 EORTC QLQ-C30 is a psychometrically and clinically validated instrument appropriate for assessing HRQoL in oncology studies. The EORTC QLQ-C30 is the most widely used cancer-specific HRQoL instrument, which contains 30 items and measures 5 functional dimensions (physical, role, emotional, cognitive and social), 3 symptom items (fatigue, nausea/vomiting, and pain), 6 single items (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial impact), and a global health and QoL scale. For the global health status or QoL and function scales, a higher value indicates a better level of function; for symptom scales and items, a higher value indicates increased severity of symptoms. Baseline and up to ~28 months
Secondary Change From Baseline in the European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) Physical Functioning Score-Items 1 to 5 The EQ-5D-5L is a standardized instrument for use as a measure of health outcome and will provide data to develop health utilities for use in health economic analyses. The 5 health state dimensions in the EQ-5D-5L include the following: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension is rated on a 5-point scale from 1 (no problem) to 5 (unable to/extreme problems). The EQ-5D-5L also includes a graded (0 to 100) vertical visual analog scale on which the participant rates his or her general state of health at the time of the assessment. This instrument has been used extensively in cancer studies and published results from these studies support its validity and reliability. Baseline and up to ~28 months
Secondary Change From Baseline in the European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) Role Functioning Score-Items 6 and 7 The EQ-5D-5L is a standardized instrument for use as a measure of health outcome and will provide data to develop health utilities for use in health economic analyses. The 5 health state dimensions in the EQ-5D-5L include the following: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension is rated on a 5-point scale from 1 (no problem) to 5 (unable to/extreme problems). The EQ-5D-5L also includes a graded (0 to 100) vertical visual analog scale on which the participant rates his or her general state of health at the time of the assessment. This instrument has been used extensively in cancer studies and published results from these studies support its validity and reliability. Baseline and up to ~28 months
See also
  Status Clinical Trial Phase
Completed NCT02857270 - A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Phase 1
Not yet recruiting NCT05985330 - Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung Cancer
Recruiting NCT05013450 - Dupilumab_Metastatic NSCLC Phase 1/Phase 2
Recruiting NCT05984277 - A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. Phase 3
Completed NCT03215810 - Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Phase 1
Completed NCT05675683 - Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib
Active, not recruiting NCT02411448 - A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) Phase 3
Recruiting NCT04410796 - Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers Phase 2
Recruiting NCT06343402 - Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer Phase 1
Recruiting NCT03300115 - Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC Phase 2
Recruiting NCT05635708 - A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer Phase 2
Terminated NCT03265080 - A Study of ADXS-NEO Expressing Personalized Tumor Antigens Phase 1
Active, not recruiting NCT05226598 - Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) Phase 3
Withdrawn NCT02639234 - Vigilâ„¢ + Nivolumab in Advanced Non-Small Cell Lung Cancer Phase 2
Recruiting NCT05364073 - Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations Phase 1
Completed NCT03926260 - Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA N/A
Active, not recruiting NCT03976375 - Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) Phase 3
Recruiting NCT05546905 - A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)
Withdrawn NCT01936961 - Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors N/A
Not yet recruiting NCT06428422 - The Impact of Probiotic on Survival and Treatment Response in Metastatic Non-small Cell Lung Cancer Patients N/A